The Food and Drug Administration said Friday it will add a new warning and other limitations to a gene therapy for Duchenne’s muscular dystrophy that's been linked to two patient deaths. The infused therapy from Sarepta Therapeutics will carry a boxed warning — the most serious type — alerting doctors and patients to the risk of potentially fatal liver failure with the treatment, the FDA said in a release. The one-time therapy, Elevidys, has been under FDA scrutiny since the company reported t

With regards to arranging an excursion, Americans have a different cluster of objections to browse. Whether it's the

"We're not certain if having widespread liquid pockets instead of a global ocean makes Titan more or less habitable."